FIELD: medicine, pharmaceutics.
SUBSTANCE: what is presented is the use of oestriol for preparing a pharmaceutical composition for vaginal administration for preventing and/or treating urogenital atrophy due to estrogen deficiency in women, wherein said composition is administered so that the patient receives a dose of oestriol 0.3 mg/day or less with this administration being daily or once every two days, once every three days or once a week for at least 3 weeks and a related method for preventing and/or treating. It is shown that the administration of oestriol in a dose of 10 times less than the standard one; it eliminates the state of vaginal atrophy.
EFFECT: invention provides the therapeutic effectiveness similar to the responses to the modern methods of treating, but with greater safety leading to a better quality of life.
14 cl, 10 tbl
